EP1525198B1 - Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de avp - Google Patents

Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de avp Download PDF

Info

Publication number
EP1525198B1
EP1525198B1 EP03753652A EP03753652A EP1525198B1 EP 1525198 B1 EP1525198 B1 EP 1525198B1 EP 03753652 A EP03753652 A EP 03753652A EP 03753652 A EP03753652 A EP 03753652A EP 1525198 B1 EP1525198 B1 EP 1525198B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
indol
chloro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03753652A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1525198A2 (fr
Inventor
Alain Aulombard
Georges Garcia
Antoine Pradines
Claudine Serradeil-Le Gal
Jean Wagnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to SI200330179T priority Critical patent/SI1525198T1/sl
Publication of EP1525198A2 publication Critical patent/EP1525198A2/fr
Application granted granted Critical
Publication of EP1525198B1 publication Critical patent/EP1525198B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the subject of the present invention is acyloxypyrrolidine derivatives, their preparation and their application in therapeutics.
  • the compounds according to the present invention have an affinity and a selectivity for the V 1b receptors or both for the V 1b and V 1a receptors of arginine vasopressin (AVP).
  • AVP arginine vasopressin
  • AVP is a hormone known for its antidiuretic effect and its effect in the regulation of blood pressure. It stimulates several types of receivers: V 1 (V 1a , V 1b ), V 2 . These receptors are located in particular in the liver, the vessels (coronary, renal, cerebral), platelets, kidney, uterus, adrenal glands, pancreas, central nervous system, pituitary gland. AVP thus exerts cardiovascular, hepatic, pancreatic, antidiuretic, platelet aggregating effects and effects on the central and peripheral nervous system, and on the uterine sphere.
  • V 1a receptors of AVP are localized in many peripheral organs and in the brain. They have been cloned, particularly in rats and humans, and they regulate the majority of the known effects of AVP: platelet aggregation; uterine contractions; the contraction of the vessels; the secretion of aldosterone, cortisol, CRF (corticotropin-releasing factor) and adrenocorticotrophic hormone (ACTH); hepatic glycogenolysis, cell proliferation and the main central effects of AVP (hypothermia, memory, ).
  • V 1b receptors were initially identified in the adenohypophysis of different animal species (rat, pig, beef, sheep, etc.) including in humans (S. JARD et al., Mol Pharmacol., 1986, 30 , 171-177, Y. ARSENIJEVIC et al., J. Endocrinol., 1994, 141 , 383-391, J. SCHWARTZ et al., Endocrinology, 1991, 129 (2), 1107-1109, Y.
  • V 1b receptors have been cloned in rats, humans and mice (Y. KEYSER, FEBS Letters, 1994, 356 , 215-220, T. SUGIMOTO et al., J. Biol Chem, 1994, 269 (43), 27088-27092, M. SAITO et al., Biochem Biophys Res Commun., 1995, 212 (3), 751-757, SJ LOLAIT et al., Neurobiology, 1996, 92 , 6783.
  • AVP via these receptors would play a crucial role in certain types of adrenal pheochromocytomas secreting AVP and thus inducing a sustained production of catecholamines at the origin of hypertension that is resistant to receptor antagonists.
  • angiotensin II and angiotensin converting enzyme inhibitors The adrenal cortex is also rich in V 1a receptors involved in the production of gluco- and mineralo-corticoids (aldosterone and cortisol).
  • AVP circulating or synthesized locally
  • Cortisol is a potent regulator of the production of ACTH, the stress hormone.
  • V 1b receptors are also considered tumor markers.
  • ACTH secreting tumors are certain pituitary tumors, some bronchial carcinomas (small cell lung cancer or SCLC), pancreatic, adrenal and thyroid, inducing Cushing's syndrome in some patients. case (J. BERTHERAT et al., Eur J Endocrinol., 1996, 135 , 173, GA WITTERT et al., Lancet, 1990, 335 , 991-994, G. DICKSTEIN et al., J. Clin Endocrinol Metab., 1996, 81 (8), 2934-2941) overexpress V 1b receptors.
  • V 1a receptors are, in turn, more specific markers of small cell lung cancer (SCLC) (PJ Woll et al., Biochem Biophys Res Commun, 1989, 164 (1), 66-73).
  • SCLC small cell lung cancer
  • the compounds according to the present invention are obvious diagnostic tools and offer a new therapeutic approach in the proliferation and detection of these tumors, at an early stage (radiolabeling, SPECT, of the English Single Photon Emission Computed Tomography; PET Scan, English Positron Emission Tomography Scanner).
  • V 1b receptors The abundant presence of the messenger of the V 1b receptors at the stomach and intestinal level, suggests involvement of AVP via this receptor on the release of gastrointestinal hormones such as cholecystokinin, gastrin or secretin (T. SUGIMOTO et al., Molecular cloning and functional expression of V 1b receptor gene, in Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research, T. SAITO, K. KUROKAWA and S. YOSHIDA ed., Elvesier Science, 1995, 409-413).
  • a selective V 1b receptor antagonist (2S, 4R) -1- [5-chloro-1 - [(2,4-dimethoxyphenyl) sulfonyl] -3- (2-methoxyphenyl) -2-oxo 2,3-Dihydro- 1H- indol-3-yl] -4-hydroxy-N, N-dimethyl-2-pyrrolidinecarboxamide, levorotatory isomer (hereinafter referred to as compound A) has been described (WO 01/55130; J. Pharmacol Exp Ther, 2002, 300 (3), 1122-1130).
  • the compounds of formula (I) comprise three asymmetric carbon atoms, the carbon atom bearing the substituent -CON (CH 3 ) 2 has the configuration (S), the carbon atom carrying the substituent -OCOR 1 has the configuration (R), and the 3-position carbon atom of indole-2-one has the (R) configuration.
  • the compounds of formula (I) may exist in the form of bases or of addition salts to organic or inorganic bases such as salts with alkali metals or alkaline earth, or salts with organic or inorganic amines. Such salts addition are part of the invention.
  • salts are advantageously prepared with pharmaceutically acceptable bases acceptable, but salts of other bases useful, for example, for purification or the isolation of the compounds of formula (I) are also part of the invention.
  • the compounds of formula (I) can exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates are also part of of the invention.
  • alkyl is meant a linear or branched alkyl radical of one to six carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl, pentyl, isopentyl, hexyl, isohexyl.
  • cycloalkyl is meant a cyclic alkyl radical of three to six carbon atoms. carbon such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • the compound of formula (I) is converted into one of its salts addition to a base.
  • the reaction is carried out in a solvent such as a chlorinated solvent such as dichloromethane, dichloroethane, chloroform, a ether such as tetrahydrofuran, dioxane, an amide such as N, N-dimethylformamide, in the presence of a base such as triethylamine, N-methylmorpholine, pyridine, 4-dimethylaminopyridine or N, N-diisopropylethylamine and at a temperature between -60 ° C and the temperature room.
  • a solvent such as a chlorinated solvent such as dichloromethane, dichloroethane, chloroform, a ether such as tetrahydrofuran, dioxane, an amide such as N, N-dimethylformamide
  • the reaction is carried out in the absence or presence a base such as pyridine, 4- (dimethylamino) pyridine, in a solvent or in a the absence of a solvent at a temperature between room temperature and reflux temperature of the reaction medium.
  • a base such as pyridine, 4- (dimethylamino) pyridine
  • a solvent it can be chosen from a chlorinated solvent such as dichloromethane, an aromatic solvent like toluene.
  • a compound of formula (I) in which R 1 represents a group -CH 2 CH 2 COOH may also be prepared by reaction of compound A with succinic anhydride, in the presence of a base such as pyridine, in a solvent or in the absence of solvent and at a temperature between room temperature and the reflux temperature of the reaction medium.
  • a base such as pyridine
  • the reaction is carried out using a condensation such as a carbodiimide such as 1,3-dicyclohexylcarbodiimide or 1,3-diisopropylcarbodiimide, an imidazole such as 1,1'-oxalyldiimidazole or N, N'-carbonyldiimidazole.
  • a condensation such as a carbodiimide such as 1,3-dicyclohexylcarbodiimide or 1,3-diisopropylcarbodiimide
  • an imidazole such as 1,1'-oxalyldiimidazole or N, N'-carbonyldiimidazole.
  • the reaction is carried out in the absence or presence of a base such as triethylamine, N, N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine or N-methylmorpholine, in a solvent such as a solvent chlorine such as dichloromethane, dichloroethane, chloroform, an ester ethyl acetate, an ether such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, a nitrile such as acetonitrile, an amide such as N, N-dimethylformamide, an aromatic such as toluene, xylene and at a temperature between -20 ° C and 80 ° C.
  • a solvent such as a solvent chlorine such as dichloromethane, dichloroethane, chloroform, an ester ethyl acetate, an ether such as diethyl ether, diis
  • the reaction can also be carried out presence of an acid catalyst such as an inorganic acid such as acid hydrochloric acid, hydrobromic acid, sulfuric acid, an organic acid acetic acid, formic acid, oxalic acid, p-toluenesulfonic acid, a Lewis acid such as boron trichloride, boron trifluoride or tribromide boron.
  • an acid catalyst such as an inorganic acid such as acid hydrochloric acid, hydrobromic acid, sulfuric acid, an organic acid acetic acid, formic acid, oxalic acid, p-toluenesulfonic acid, a Lewis acid such as boron trichloride, boron trifluoride or tribromide boron.
  • the reaction is carried out in a solvent such as a chlorinated solvent such as dichloromethane, dichloroethane, chloroform, an ether such as ether diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, a ketone such as acetone, methyl ethyl acetone, methyl isobutyl ketone, a nitrile acetonitrile, an amide such as N, N-dimethylformamide and at a temperature between 0 ° C and the reflux temperature of the solvent.
  • a solvent such as a chlorinated solvent such as dichloromethane, dichloroethane, chloroform, an ether such as ether diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, a ketone such as acetone, methyl ethyl acetone, methyl isobutyl ket
  • a compound of formula (I) in which R 1 represents a hydrogen atom may also be prepared by reaction of compound A with formic acid, in the presence of acetic anhydride and a base such as pyridine, at a temperature of temperature between 0 ° C and room temperature.
  • step a) compound A is reacted with phenyl chloroformate, in presence of a base such as pyridine or triethylamine, in a solvent such as dichloromethane or without solvent and at a temperature between 0 ° C and 100 ° C.
  • a base such as pyridine or triethylamine
  • step b) the reaction of compound B with the compound of formula (III) is carried out in a solvent such as dichloromethane or tetrahydrofuran or a mixture of these solvents and at a temperature between -60 ° C and the reflux temperature of solvent.
  • a solvent such as dichloromethane or tetrahydrofuran or a mixture of these solvents and at a temperature between -60 ° C and the reflux temperature of solvent.
  • the compounds of formula (I) thus obtained may subsequently be separated from reaction medium and purified by conventional methods, for example by crystallization or chromatography.
  • Compound A is prepared according to the method described in the application WO 01/55130.
  • the functional derivatives of the acids of formula (II) are commercial, known or prepared according to known methods.
  • the invention according to another of its aspects, also relates to compound B.
  • Proton magnetic resonance spectra ( 1 H NMR) are recorded at 200 MHz in DMSO-d 6 , using the peak of DMSO-d 6 as a reference.
  • the chemical shifts ⁇ are expressed in parts per million (ppm).
  • the signals observed are expressed as follows: s: singlet; it is: widened singlet; d: doublet; dd: double doublet; t: triplet; q: quadruplet; m: massive; mt: multiplet.
  • the compounds according to the invention have been the subject of biochemical studies.
  • the affinity of the compounds of formula (I) according to the invention for the V 1b receptors of arginine vasopressin was determined in vitro using the method described by Y. DE KEYSER et al., Febs Letters, 1994, 356. , 215-220. This method consists of studying in vitro the displacement of tritiated arginine-vasopressin ([ 3 H] -AVP) at the V 1b receptors present on adenohypophyseal or cellular membrane preparations carrying rat V 1b or human receptors. Inhibitory concentrations of 50% (IC 50 ) of the binding of tritiated arginine-vasopressin of the compounds according to the invention are generally less than 5.0 ⁇ 10 -9 M. For example, the compound of Example 1 has a CI 50 3.4.10 -9 M for human V 1b receptors.
  • the affinity of the compounds of formula (I) according to the invention for the V 1a receptors of arginine-vasopressin was determined in vitro using the method described by M. THIBONNIER et al., J. Biol. Chem., 1994, 269 , 3304-3310. This method consists of studying in vitro the displacement of tritiated arginine-vasopressin ([ 3 H] -AVP) at the V 1a receptors present on membrane or cell preparations carrying the rat or human V 1a receptors.
  • Some compounds of formula (I) also have an affinity for arginine vasopressin V 1a receptors with IC 50 values of the order of 10 -8 M. For example, the compound of Example 1 has an IC 50 8.4 ⁇ 10 -8 M for human V 1a receptors.
  • the compound A of the prior art with an IC 50 of 1.0x10 -8 M for V 1b receptors and human IC 50 of 3,1.10 -7 M for human V 1a receptors.
  • the affinity of the compounds of formula (I) according to the invention for the V 2 receptors of vasopressin has also been studied (method described by M. Birnbaumer et al., Nature (Lond.), 1992, 357 , 333-335. ). The compounds studied have little or no affinity for V 2 receptors.
  • the compounds according to the invention can therefore be used for the preparation of medicaments, in particular medicaments intended to prevent or treat any pathology in which arginine vasopressin and / or its V 1b receptors or both its V 1b receptors and its V 1a receptors are involved.
  • the subject of the invention is medicaments which comprise a compound of formula (I), or an addition salt thereof to a base pharmaceutically acceptable, or a solvate or a hydrate of the compound of formula (I).
  • the compounds according to the invention can be used, in humans or at home.
  • the animal in the treatment or prevention of various vasopressin-dependent conditions such as cardiovascular conditions; like hypertension, pulmonary hypertension, heart failure, myocardial infarction, or coronary vasospasm, particularly in the smoker, Raynaud's disease, unstable angina and PTCA (from the English percutaneous transluminal coronary angioplasty), cardiac ischemia, dysregulation of hemostasis; the affections of the central nervous system such as migraine, cerebral vasospasm, haemorrhage cerebral edema, depression, anxiety, stress, disorders emotional, obsessive-compulsive disorder, panic attacks, states psychotic, memory disorders for example; diseases of the renal system such as renal vasospasm, renal cortex necrosis, diabetes insipidus nephrogenic; disorders of the gastric system such as gastric vasospasm, hepatocirrhosis, ulcers, pathology of vomiting, for example nausea
  • the compounds according to the invention can also be used in the treatment of disorders of sexual behavior; in women, the compounds according to The invention can be used to treat dysmenorrhea or premature labor.
  • the compounds according to the invention can also be used in the treatment of small cell lung cancer; hyponatremic encephalopathies; of pulmonary syndrome, Meniere's disease; glaucoma, cataracts; of obesity; type II diabetes; atherosclerosis; Cushing's syndrome; of the insulin resistance; hypertriglyceridemia; in post-operative treatments, especially after abdominal surgery.
  • the compounds according to the invention can also be used in the treatment or the prevention of all pathologies resulting from stress such as fatigue and its syndromes, ACTH-dependent disorders, cardiac disorders, pain, changes in gastric emptying, faecal excretion (colitis, colon syndromes irritable, Crohn's disease), acid secretion, hyperglycemia, immunosuppression, inflammatory processes (rheumatoid arthritis and osteoarthritis), multiple infections, cancers, asthma, psoriasis, allergies and various neuropsychiatric disorders such as anorexia nervosa, bulimia nervosa, mood disorders, depression, anxiety, sleep disorders, states of panic, phobias, obsession, disorders of pain perception (fibromyalgia), neurodegenerative diseases (Alzheimer's disease, Parkinson's, Huntington's disease), substance dependence, stress hemorrhagic, muscle spasm, hypoglycemia.
  • the compounds according to the invention may also be used in the treatment or prevention of chronic
  • the compounds according to the invention can also be used as psychostimulants, causing the increase of the awakening, the emotional reactivity face to the environment and facilitating adaptation.
  • compositions pharmaceutical compositions comprising, as an active ingredient, a compound according to the invention.
  • These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, a solvate or hydrate said compound, as well as at least one pharmaceutically excipient acceptable.
  • Said excipients are chosen according to the pharmaceutical form and the mode desired administration, among the usual excipients which are known to humans of career.
  • compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal the active ingredient of formula (I) above, or its salt, solvate or hydrate, may be administered in unit dosage form, in admixture with pharmaceutical excipients animal and human beings for the prophylaxis or treatment of disorders or diseases above.
  • Appropriate unitary forms of administration include forms by orally, such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, forms of administration sublingual, oral, intratracheal, intraocular, intranasal, inhalation, forms of topical, transdermal, subcutaneous, intramuscular or intravenous forms of rectal administration and implants.
  • the compounds according to the invention can be used in creams, gels, ointments or lotions.
  • a unitary form of administration of a compound according to the invention in tablet form may comprise the following components: Compound according to the invention 50.0 mg mannitol 223.75 mg Croscaramellose sodium 6.0 mg Corn starch 15.0 mg Hydroxypropylmethylcellulose 2.25 mg Magnesium stearate 3.0 mg
  • the dose of active ingredient administered per day can reach 0.01 to 100 mg / kg, in one or more doses, preferably 0.02 to 50 mg / kg.
  • the appropriate dosage for each patient is determined by the physician according to the mode of administration, weight and response of said patient.
  • the present invention also relates to a method of treatment of the pathologies indicated above which includes administering to a patient an effective dose of a compound according to the invention, or one of its pharmaceutically acceptable salts or hydrates or solvates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP03753652A 2002-07-19 2003-07-17 Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de avp Expired - Lifetime EP1525198B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI200330179T SI1525198T1 (sl) 2002-07-19 2003-07-17 Derivati aciloksi pirolidina in njihova uporaba kot ligandi receptorjev V1b ali V1b in V1a od AVP

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0209242 2002-07-19
FR0209242A FR2842527B1 (fr) 2002-07-19 2002-07-19 Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
PCT/FR2003/002262 WO2004009585A2 (fr) 2002-07-19 2003-07-17 Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b et v1a de avp

Publications (2)

Publication Number Publication Date
EP1525198A2 EP1525198A2 (fr) 2005-04-27
EP1525198B1 true EP1525198B1 (fr) 2005-12-07

Family

ID=29797610

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03753652A Expired - Lifetime EP1525198B1 (fr) 2002-07-19 2003-07-17 Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de avp

Country Status (28)

Country Link
US (1) US7202267B2 (ru)
EP (1) EP1525198B1 (ru)
JP (1) JP4264414B2 (ru)
CN (1) CN100425608C (ru)
AR (1) AR040571A1 (ru)
AT (1) ATE312092T1 (ru)
AU (1) AU2003271815B8 (ru)
BR (1) BR0312800A (ru)
CA (1) CA2492224A1 (ru)
DE (1) DE60302670T2 (ru)
DK (1) DK1525198T3 (ru)
EA (1) EA008444B1 (ru)
ES (1) ES2254962T3 (ru)
FR (1) FR2842527B1 (ru)
HK (1) HK1074444A1 (ru)
HR (1) HRP20041231A2 (ru)
IL (1) IL165942A (ru)
IS (1) IS2487B (ru)
ME (1) MEP12408A (ru)
MX (1) MXPA05000822A (ru)
NO (1) NO20050292L (ru)
NZ (1) NZ537615A (ru)
PL (1) PL375309A1 (ru)
RS (1) RS20050018A (ru)
TW (1) TWI274751B (ru)
UA (1) UA78805C2 (ru)
WO (1) WO2004009585A2 (ru)
ZA (1) ZA200500478B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4618127B2 (ja) 2003-08-28 2011-01-26 大正製薬株式会社 １，３−ジヒドロ−２ｈ−インドール−２−オン誘導体
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
DE102005015957A1 (de) * 2005-03-31 2006-10-05 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
US8350043B2 (en) 2005-06-07 2013-01-08 Pharmacopeia, Inc. Azinone and diazinone V3 inhibitors for depression and stress disorders
CA2663161C (en) 2006-09-11 2014-10-28 N.V. Organon Quinazolinone and isoquinolinone acetamide derivatives
CN103864658B (zh) * 2014-03-06 2016-06-15 南京工业大学 氮杂环丁酮衍生物及其制备方法与应用
CN104447489B (zh) * 2014-12-29 2017-01-11 南京工业大学 3,4-二芳基马来酰亚胺衍生物及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804114B1 (fr) * 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
NZ537615A (en) 2006-11-30
HRP20041231A2 (en) 2005-02-28
FR2842527A1 (fr) 2004-01-23
TW200410957A (en) 2004-07-01
AU2003271815B8 (en) 2009-04-30
WO2004009585A3 (fr) 2004-05-06
CN100425608C (zh) 2008-10-15
IL165942A (en) 2010-04-15
CN1681806A (zh) 2005-10-12
PL375309A1 (en) 2005-11-28
EA200500032A1 (ru) 2005-08-25
EP1525198A2 (fr) 2005-04-27
JP2005537271A (ja) 2005-12-08
EA008444B1 (ru) 2007-06-29
ES2254962T3 (es) 2006-06-16
ATE312092T1 (de) 2005-12-15
FR2842527B1 (fr) 2005-01-28
IL165942A0 (en) 2006-01-15
MEP12408A (en) 2010-06-10
UA78805C2 (en) 2007-04-25
AU2003271815A1 (en) 2004-02-09
AU2003271815B2 (en) 2009-03-12
AR040571A1 (es) 2005-04-13
HK1074444A1 (en) 2005-11-11
RS20050018A (en) 2007-06-04
NO20050292L (no) 2005-04-19
DE60302670D1 (de) 2006-01-12
ZA200500478B (en) 2006-07-26
DK1525198T3 (da) 2006-04-18
US20050192335A1 (en) 2005-09-01
US7202267B2 (en) 2007-04-10
MXPA05000822A (es) 2005-08-29
DE60302670T2 (de) 2006-09-07
BR0312800A (pt) 2005-04-19
JP4264414B2 (ja) 2009-05-20
WO2004009585A2 (fr) 2004-01-29
TWI274751B (en) 2007-03-01
IS2487B (is) 2008-12-15
CA2492224A1 (en) 2004-01-29
IS7641A (is) 2005-01-12

Similar Documents

Publication Publication Date Title
EP1254134B1 (fr) Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands pour les recepteurs v1b ou v1b et v1a de l'arginine-vasopressine
EP1255751B1 (fr) Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'arginine-vasopressine
EP1419150B1 (fr) Derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
JP5086480B2 (ja) グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体
TWI360541B (en) Novel compounds
EP1259505B1 (fr) Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b ou v1b et v1a de l'arginine-vasopressine
EP1296976B1 (fr) Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine
EP0501892B1 (fr) Dérivés hétérocycliques diazotés N-substitués par un groupement biphénylméthyle, leur préparation, les compositions pharmaceutiques en contenant
EP2294068B1 (fr) DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE
EP2265582B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CA2696237A1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
US7202267B2 (en) Acyloxypyrrolidine derivatives, preparation thereof and application thereof in therapeutic
KR20050019896A (ko) 아실옥시피롤리딘 유도체, 및 ｖ1ｂ 수용체 또는 ｖ1ｂ 및ｖ1ａ 수용체 모두의 리간드로서의 그의 용도

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074444

Country of ref document: HK

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REF Corresponds to:

Ref document number: 60302670

Country of ref document: DE

Date of ref document: 20060112

Kind code of ref document: P

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20060316

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E000278

Country of ref document: EE

Effective date: 20060222

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20060400793

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2254962

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1074444

Country of ref document: HK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E000473

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060908

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20100625

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20110628

Year of fee payment: 9

Ref country code: GR

Payment date: 20110610

Year of fee payment: 9

Ref country code: MC

Payment date: 20110629

Year of fee payment: 9

Ref country code: CZ

Payment date: 20110616

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20110614

Year of fee payment: 9

Ref country code: LU

Payment date: 20110718

Year of fee payment: 9

Ref country code: EE

Payment date: 20110615

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20110712

Year of fee payment: 9

Ref country code: DK

Payment date: 20110712

Year of fee payment: 9

Ref country code: FR

Payment date: 20110727

Year of fee payment: 9

Ref country code: IE

Payment date: 20110712

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20110712

Year of fee payment: 9

Ref country code: ES

Payment date: 20110817

Year of fee payment: 9

Ref country code: DE

Payment date: 20110713

Year of fee payment: 9

Ref country code: SE

Payment date: 20110712

Year of fee payment: 9

Ref country code: SK

Payment date: 20110712

Year of fee payment: 9

Ref country code: SI

Payment date: 20110617

Year of fee payment: 9

Ref country code: PT

Payment date: 20110713

Year of fee payment: 9

Ref country code: HU

Payment date: 20110707

Year of fee payment: 9

Ref country code: GB

Payment date: 20110713

Year of fee payment: 9

Ref country code: AT

Payment date: 20110628

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20110715

Year of fee payment: 9

Ref country code: BE

Payment date: 20110712

Year of fee payment: 9

Ref country code: IT

Payment date: 20110719

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20111114

Year of fee payment: 9

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20130117

BERE Be: lapsed

Owner name: *SANOFI-AVENTIS

Effective date: 20120731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60302670

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60302670

Country of ref document: DE

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20130201

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM9D

Effective date: 20120717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20060400793

Country of ref document: GR

Effective date: 20130104

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 312092

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120717

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120717

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60302670

Country of ref document: DE

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE

Effective date: 20130205

Ref country code: DE

Ref legal event code: R081

Ref document number: 60302670

Country of ref document: DE

Owner name: SANOFI, FR

Free format text: FORMER OWNER: SANOFI-AVENTIS, PARIS, FR

Effective date: 20130205

Ref country code: DE

Ref legal event code: R081

Ref document number: 60302670

Country of ref document: DE

Owner name: SANOFI-AVENTIS, FR

Free format text: FORMER OWNER: SANOFI-AVENTIS, PARIS, FR

Effective date: 20130205

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20130221

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 482

Country of ref document: SK

Effective date: 20120717

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E000278

Country of ref document: EE

Effective date: 20120731

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120718

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120718

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130201

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130201

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130117

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120718

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60302670

Country of ref document: DE

Effective date: 20130201

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120717

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120731